A diagnostic system for assessing cardiovascular health is provided that incorporates a microfluidic platform and sensors that capture inflammatory monocytes. The portable microfluidic platform shears activated monocytes in a small volume of blood (50 L) over a glass substrate that mimics the stress and molecular constituents of an inflamed artery. The sensor utilizes CD11c antibodies and/or VLA-4 ligands to capture cells. The device captures a subset of inflammatory subset of activated white blood cells that play a critical role in the progression of cardiovascular disease and whose numbers in the blood and the efficiency of capture directly correlate with risk and pathogenesis of cardiovascular disease. The risk of future cardiac events can be assessed. The system can facilitate early detection of cardiovascular disease and can guide risk factor modification and therapy following treatment.

The present invention concerns the use of VCAM-1, ICAM-1 and/or PIGF as biomarkers for predicting the outcome of the treatment with aflibercept, or ziv-aflibercept of a patient suspected to suffer from a cancer.

Provided is a noninvasive method for determining the presence of a symptom of a hepatic disease such as nonalcoholic fatty liver disease with a higher diagnostic accuracy. A method for discriminate between nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH), the method comprising: (1) a step of measuring the quantities of marker molecules contained in blood collected from a subject; (2) a step of determining an index value from a normalized score calculated based on the quantities of the marker molecules belonging to the same group; and (3) a step of determining that the subject is possibly affected with NASH in the case that the index value is larger than a reference value.

The present invention provides methods for predicting the likelihood of mucosal healing in an individual with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis (UC). In addition, the present invention provides methods for monitoring the progression of mucosal healing in an individual with a disease such as IBD. Information on mucosal healing status derived from the use of the present invention can also aid in optimizing therapy and/or monitoring the therapeutic efficiency of an anti-TNF inhibitor drug.

The present invention provides biomarker-based methods for diagnosing stroke in a patient suspected of having suffered a stroke, and also for discriminating between ischemic stroke and transient ischemic attack. Substrates comprising probes for specific combinations of biomarkers useful in the methods of the invention are also described.

The present invention provides compositions and methods useful for diagnosing, monitoring the progression, identifying the location, and monitoring the treatment response in ovarian cancer based on detecting and locating VCAM-1 expression.

The present invention provides methods for predicting the likelihood of mucosal healing in an individual with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis (UC). In addition, the present invention provides methods for monitoring the progression of mucosal healing in an individual with a disease such as IBD. Information on mucosal healing status derived from the use of the present invention can also aid in optimizing therapy and/or monitoring the therapeutic efficiency of an anti-TNF inhibitor drug.